Today's Rundown MSKCC’s Maura Dickler to become Eli Lilly’s new late-stage cancer R&D lead AM-Pharma still on track with sepsis drug despite mixed phase 2 readout Kapeller leaves Nimbus, ending CSO stint defined by virtual drug discovery successes MyoKardia delivers in midstage trial, revs up for phase 3 AI-driven drug discovery startup Atomwise raises $45M series A WuXi NextCODE and Google Cloud partner to enhance global genomic access EuroBiotech Report—Reed exits Roche, Autolus CAR-T IPO, U.K. seeks EMA role, cancer vaccines and cystic fibrosis data FiercePharmaAsia—Merck-Eisai’s Lenvima deal, JW’s $90M series A, novel HIV drug Chutes & Ladders—Parexel co-founder ends 35-year run as CEO Featured Story | | | Friday, March 9, 2018 Memorial Sloan Kettering Cancer Center’s Maura Dickler, M.D., has been lined up as Lilly’s new VP of late-phase development in oncology. |
|
|
Top Stories Friday, March 9, 2018 The Dutch biotech's recAP candidate has shown a 40% reduction in mortality in patients with sepsis-related acute kidney injury. Friday, March 9, 2018 Rosana Kapeller, M.D., Ph.D., has left Nimbus Therapeutics after eight years in the CSO post. Kapeller departs having helped put virtual drug discovery on the map and land deals with Celgene, Genentech and Gilead. Thursday, March 8, 2018 MyoKardia's hypertrophic cardiomyopathy drug, mavacamten, met primary and secondary endpoints in a phase 2 trial. The data will inform dosing in the upcoming pivotal study. Friday, March 9, 2018 Artificial intelligence-driven drug discovery has attracted many investments lately. Atomwise, the first company to commercialize deep neural networks for drug discovery, joined the growing list with a $45 million series A. Friday, March 9, 2018 Genomics giant WuXi NextCODE is partnering with Google Cloud to establish a global platform standard for using genome data to advance health worldwide. Thursday, March 8, 2018 In this week's EuroBiotech Report, Reed leaves Roche, Autolus files for Nasdaq IPO, the U.K. pitches for an ongoing EMA role and more. Friday, March 9, 2018 Merck signed a deal potentially worth $5.8 billion for half of Lenvima's sales; Juno and WuXi AppTec's CAR-T joint venture got $90 million in a series A; the FDA approved TaiMed Biologics’ novel HIV drug Trogarzo manufactured by WuXi Biologics; plus more pharma industry news from Asia. Friday, March 9, 2018 Parexel co-founder Joseph von Rickenbach hands the reins to former INC Research helmsman Jamie Macdonald, Roche promotes William Pao to replace departing John Reed as pRED head, Moderna loses its CSO of infectious diseases, plus more hirings, firings and retirings throughout the industry. | This week's sponsor is cobra:bio. | | | 1ml Long Syringe Line Now Available
In response to customer demand, Cobra has invested in an expansion of capabilities for batches up to 20k units. Today ~80% of the market for high value, low volume biologicals utilises the 1ml long format. More... |
Resources Sponsored by: MK&A There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now! Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! |
